FAP-targeted radiopharmaceutical therapy shows broad effectiveness across multiple cancers

A novel radiopharmaceutical therapy approach that targets fibroblast activation protein (FAP)—which is highly expressed in many types of cancer—is safe and effective for patients, according to a new study published in the June issue of the Journal of Nuclear Medicine. In a study of nearly 90 patients with 21 different types of cancer, FAP-targeted radiopharmaceutical therapy achieved objective responses in approximately two-thirds of patients and disease control in more than 80%.